About Anton Mat

This author has not yet written his bio.
Meanwhile let's just say that we are proud Anton Mat contributed with 10 entries.

Entries by Anton Mat

ISA Pharmaceuticals and Cancer Focus Fund Announce $5 Million Investment to Support First-in-Human Trial of ISA’s Novel Immunotherapy ISA103 in Uveal Melanoma

ISA Completes Enrolment in Randomized Double Blind Phase 2 Clinical Trial of ISA101b in HPV16 induced Oropharyngeal Cancer

First-in-Human Study: Amplivant® Adjuvant Boosts Immune Response of Synthetic Long Peptide Immunotherapy

Professor Melief to receive 2022 SITC Pedro J. Romero Award

ISA Pharmaceuticals’ Chief Scientific Officer Prof. Dr. Melief Awarded Fellowship at the Society for Immunotherapy of Cancer

ISA to Present at Business Conferences in May 2022

ISA Pharmaceuticals announces the start of clinical trial using its novel AMPLIVANT® technology

Long term study confirms efficacy of our T-cell activating immunotherapy in combination with checkpoint inhibitor

ISA Pharmaceuticals to Attend Multiple In Person Conferences in Early 2022